Analysis of Myeloperoxidase Levels in Serum of Patients with Colorectal Cancer

Background: Chronic inflammation significantly contributes to cancer progression, including colorectal cancer (CRC). Myeloperoxidase (MPO), a key enzyme produced by neutrophils, generates reactive oxygen species (ROS) that lead to tissue damage and intensify inflammation. Objectives: This study examines MPO levels in CRC patients compared to healthy controls and explores the association between elevated MPO levels and other inflammatory markers, including lactate dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR). Methods: The study included 60 participants divided into two groups: Thirty patients diagnosed with CRC and 30 healthy controls, aged between 35 and 75 years. Colorectal cancer patients and healthy controls were matched for age and sex, with no significant demographic differences between groups. Myeloperoxidase, LDH, and ESR levels were measured in blood samples using standard biochemical techniques. Statistical analysis was conducted to compare levels between groups, using chi-square and t-tests to confirm the comparability of demographic characteristics. Results: Myeloperoxidase levels were significantly elevated in CRC patients compared to healthy controls (P < 0.01), indicating increased neutrophil activity and chronic inflammation. Colorectal cancer patients also showed elevated LDH and ESR levels, suggesting widespread cellular injury and an active inflammatory response. Furthermore, increased MPO levels positively correlated with LDH and ESR, indicating that MPO-driven ROS may contribute to tissue damage and systemic inflammation. Conclusions: The results demonstrate that elevated MPO levels in CRC patients are linked to increased inflammation and tissue damage. This study identifies MPO as a potential biomarker for CRC progression and suggests that targeting MPO-mediated inflammation could provide new therapeutic strategies for managing CRC. Further research is necessary to investigate the regulation of MPO and its potential as a therapeutic target in CRC patients.